NASDAQ:BRTX - Nasdaq - US0906556065 - Common Stock - Currency: USD
– Underscores high unmet need for a therapeutic alternative to opioids and surgical interventions – – Reflects positive preliminary Phase 2 Safety and...
– Covers cGMP manufacturing processes – – Expected to provide protection until April 29, 2040 – MELVILLE, N.Y., Dec. 05, 2024 (GLOBE NEWSWIRE) --...
BioRestorative Therapies shares promising Phase 2 trial results for BRTX-100, showing significant pain reduction and functional improvement in cLDD patients.
– Blinded preliminary data demonstrate a positive trend and clear signal in Primary and Secondary endpoints – – Patient reported efficacy outcomes show a...
– Allows for the processing of allogeneic (non-autologous) donor tissue material, including stem cells, for medical research – MELVILLE, N.Y., Nov. 05,...
MELVILLE, N.Y., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a...
MELVILLE, N.Y., Sept. 19, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioRestorative Therapies (NASDAQ:BRTX) just reported results for the second qua...
BRTX stock results show that BioRestorative Therapies beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
MELVILLE, N.Y., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a...
- New journal section will focus on emerging and translation work in the field of regenerative medicine - MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE)...
– Adds to comprehensive patent portfolio underlying novel ThermoStem® technology platform – – Expanding intellectual property estate expected to help...
- Significant YoY improvement in operating performance - - Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - MELVILLE,...
Sharps Technology stock is up on Thursday with heavy trading of STSS shares after the company signed a $30 million purchase order.
BioRestorative Therapeutics stock is up on Thursday with heavy trading of BRTX shares after announcing licensing negotiations.
- Brown adipose derived stem cells with brown adipogenic potential would represent a new modality for the treatment of obesity and related metabolic...
BRTX stock results show that BioRestorative Therapies beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage...
MELVILLE, N.Y., May 24, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical...
MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical...
— New therapeutic candidate developed using Company’s patented ThermoStem® platform — — Candidate has potential to serve as an adjuvant to existing...
- Company to provide update on exciting new commercial agreement, as well as Phase 2 clinical trial in Spine and preclinical development program in Obesity...
— Leading regenerative medicine and aesthetics innovators collaborate to build a vertically integrated, best-in-class biocosmeceutical platform — —...
— Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative...